Per Pfeiffer

Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts

T. Sjöblom, T. Kuopio, H. Sorbye, 2023, International journal of cancer.

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

H. Sorbye, B. Glimelius, L. Balteskard, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

H. Sorbye, E. Kure, T. Guren, 2016 .

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

H. Sorbye, E. Kure, T. Guren, 2016 .

Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group.

H. Sorbye, E. Kure, E. Skovlund, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).

H. Sorbye, P. Flygare, B. Glimelius, 2024, Acta oncologica.

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.

K. Spindler, O. Lingjærde, H. Sorbye, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.